Akèy › Kansè nan tete › Oregon
Etid klinik pou Kansè nan tete nan Oregon
41 etid pou Kansè nan tete ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon PC, Eugene
- Northwest Cancer Specialists, Portland
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- ak 7 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Compass Oncology - Rose Quarter Cancer Center, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07701941A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oregon Health and Science University, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- St Charles Bend Cancer Center, Bend
- Providence Portland Medical Center, Portland
- St. Charles Cancer Center - Redmond, Redmond
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
- Oregon Oncology Specialists, Salem
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Oncology Associates of Oregon, P.C, Eugene
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07100106Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Oregon Health & Science University, Knight Cancer Institute, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- ak 10 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Willamette Valley Cancer Institute, Eugene
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Hematology Oncology Associates, Medford
- Compass Oncology - Northwest Cancer Specialists, Tigard
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 6, 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Saint Charles Health System, Bend
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- ak 6 plis
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
- Samaritan Pastega Regional Cancer Center, Corvallis
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Jul 17, 2026 · NCT07055854Identifying and Caring for Individuals With Inherited Cancer Syndrome
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT04494945First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Oncology Associates of Oregon, Springfield
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07558733177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
- OHSU Knight Cancer Institute, Portland
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Jun 5, 2026 · NCT04529044I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Oregon Health & Science Institute (OHSU), Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Clackamas Radiation Oncology Center, Clackamas
- Legacy Mount Hood Medical Center, Gresham
- Providence Newberg Medical Center, Newberg
- ak 5 plis
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Willamette Valley Cancer Institute and Research Center, Eugene
- Legacy Good Samaritan Medical Center, Portland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2025 · NCT03053193EMBRACE: Exercising Together
- OHSU Knight Cancer Institute, Portland
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou May 29, 2025 · NCT06049355Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.